AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$AZN

Sharma Mani purchased $3K of AZN

Sharma Mani (See Remarks) purchased 20 shares of ASTRAZENECA PLC (AZN) at $160.57 on 2026-08-08.

Original reporting
SEC EDGAR · Sharma Mani
Published Sep 11, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AZN
Neutral
low confidence
Mentioned
$AZN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AZNNeutralLow
01

Why it matters

The disclosed purchase is minor and unlikely to move the stock, but it confirms insider activity.

02

Market read

Low relevance; a routine insider purchase with minimal market impact.

03

What to watch

Insider may be accumulating for a future larger purchase; monitor subsequent filings.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions; required to be reported promptly.

Company-level read

Ticker impact

$AZNNeutralLow confidence
Context

Officer Sharma Mani purchased 20 shares of AstraZeneca at $160.57 each, total $3.25K, filing on 2026-09-11.

Expected impact

minimal, no immediate move expected

Evidence & confidence

Purchase size is tiny relative to market cap; insider is not a major holder change.

Market effects

Sector

None; AstraZeneca operates in pharma sector with no broader effect from this tiny trade.

Regional

None; transaction is US‑listed ADR, no regional ripple.

Global

None

Counterpoint

What could challenge this read

Even small insider buys can signal confidence; could be a subtle bullish cue.

Key entities

  • Company
    AstraZeneca PLC

    Global pharmaceutical company, ticker AZN.

  • Officer
    Sharma Mani

    Insider reporting the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AZN insider trading history →

Related articles

$AZNHighAI 9/10

AstraZeneca Weighs Roughly $10 Billion Takeover of Rhythm Pharmaceuticals, Sending Shares Up 28% — BigGo Finance

AstraZeneca has proposed a $10 billion takeover of Rhythm Pharmaceuticals, valuing it at up to $134 per share. Rhythm's shares rose 28% to $110.68, increasing its market value to $7.64 billion. The deal would expand AstraZeneca's specialty-medicine pipeline, focusing on rare diseases and obesity. AstraZeneca's market cap is $292 billion. Both companies declined to comment.

finance.biggo.com